<DOC>
	<DOCNO>NCT02442687</DOCNO>
	<brief_summary>To evaluate safety potential efficacy two dose level JKB-121 ( 5 mg twice daily 10 mg twice daily ) reduce liver fat and/or liver biochemistry compare placebo patient biopsy-proven nonalcoholic steatohepatitis</brief_summary>
	<brief_title>JKB-121 Treatment Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description>JKB-121 long-acting small molecule efficacious weak antagonist TLR-4 receptor . It non-selective opioid antagonist show prevent lipopolysaccharide ( LPS ) induce inflammatory liver injury methionine/choline deficient diet fed rat model nonalcoholic fatty liver disease . In vitro , JKB-121 neutralize reduce LPS-induced release inflammatory cytokine , deactivate hepatic stellate cell , inhibit hepatic stellate cell proliferation , collagen expression . Inhibition TLR4 signal pathway may provide effective therapy prevention inflammatory hepatic injury hepatic fibrosis patient nonalcoholic steatohepatitis . This study evaluate safety potential efficacy two dose level JKB-121 ( 5 mg twice daily 10 mg twice daily ) reduce liver fat and/or liver biochemistry compare placebo patient biopsy-proven nonalcoholic steatohepatitis .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Provision write informed consent 3 . Biopsyproven NASH within 12 month screen 4 . ALT &gt; 40 U/L woman &gt; 60 U/L men screen least previous 12 month . 5 . HBA1C ≤ 9.0 1 . Any chronic liver disease NASH 2 . Cirrhosis , assess clinically histologically 3 . Presence vascular liver disease 4 . BMI ≤ 25 kg/m2 5 . Excessive alcohol use ( &gt; 20 g/day ) within past 2 year 6 . AST ALT &gt; 250 U/L . 7 . Type 1 diabetes mellitus 8 . Bariatric surgery past 5 year . 9 . Weight gain &gt; 5 % past 6 month &gt; 10 % change past 12 month . 10 . Contraindication MRI 11 . Inadequate venous access 12 . HIV antibody positive , hepatitis B surface antigen positive ( HBsAg ) , Hepatitis C virus ( HCV ) RNA positive . 13 . Receiving elemental diet parenteral nutrition 14 . Chronic pancreatitis pancreatic insufficiency 15 . Any history complication cirrhosis 16 . Concurrent condition : Inflammatory bowel disease Significant cardiac disease chronic infection immune mediate disease Any malignant disease Prior solid organ transplant Any concurrent condition , opinion investigator , could impact adversely subject participate interpretation study data . 17 . Concurrent medication may treat NASH 18 . HbA1C &gt; 9.0 % 19 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>